
Sign up to save your podcasts
Or
Alastair and Praveen are joined by Dr. Campbell Rogers, CMO and executive VP at HeartFlow, to discuss the recently-published FORECAST trial. What are the economic and clinical outcomes of selective FFRct use in stable chest pain? Tune in and enjoy!
5
1818 ratings
Alastair and Praveen are joined by Dr. Campbell Rogers, CMO and executive VP at HeartFlow, to discuss the recently-published FORECAST trial. What are the economic and clinical outcomes of selective FFRct use in stable chest pain? Tune in and enjoy!
38,546 Listeners
90,458 Listeners
32,105 Listeners
170 Listeners
872 Listeners
111,102 Listeners
135 Listeners
7,633 Listeners
60 Listeners
37 Listeners